EHA® 2023 Insights: "Preliminary Results From the Ph1/2 RUBY Trial of EDIT-301 in Patients With Severe Sickle Cell Disease Using Highly Specific and Efficient ASCAS12A Enzyme"

178 views
June 23, 2023
0 Comments
Login to view comments. Click here to Login